Results 71 to 80 of about 2,262 (198)

Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy

BMEMat, Volume 3, Issue 1, March 2025.
This review provides a brief overview of several of the major, and potentially life‐threatening, toxicities associated with CAR T cell therapies and discusses various examples of the genetic and chemical engineering strategies employed to effectively mitigate such toxicities in preclinical models and clinical studies. Abstract Chimeric antigen receptor
Tyler Wolter, Yixin Wang, Quanyin Hu
wiley   +1 more source

NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015
The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin   +2 more
doaj  

A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir

Case Reports in Gastroenterology, 2017
Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b.
Kazuo Tarao, Akira Sato
doaj   +1 more source

New Insights Into Hepatic Impairment (HI) Trials

Clinical and Translational Science, Volume 18, Issue 1, January 2025.
ABSTRACT Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these data into various categories and connect the effect by ...
Sebastian Haertter, Maximilian Lobmeyer, Brian C. Ferslew, Pallabi Mitra, Thomas Arnhold   +4 more
wiley   +1 more source

Chemogenetic Tools in Focus: Proximity, Conformation, and Sterics

Chemistry–Methods, Volume 4, Issue 6, June 2024.
Chemogenetic tools have been widely applied to interrogate dynamic biological processes. They are genetically encoded systems that are controlled by user‐defined chemicals. In this review, chemogenetic tool designs for various biological applications are introduced and discussed.
Jiaqi Shen, Guanwei Zhou, Wenjing Wang
wiley   +1 more source

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy

Viruses, 2015
Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA ...
Kazuaki Chayama, C. Nelson Hayes
doaj   +1 more source

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Liver International, Volume 44, Issue 5, Page 1075-1092, May 2024.
Abstract Background and Aims The beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached.
Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto   +6 more
wiley   +1 more source

Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C

, 2020
Introduction: Hepatitis C virus (HCV) is estimated to infect approximately 70 million people worldwide. If left untreated, chronic infection can progress to cirrhosis, liver failure or hepatocellular carcinoma. The advent of new direct-acting antivirals (
Zappulo E., Scotto R., Pinchera B., Gentile I., Buonomo A. R., Maraolo A. E.   +5 more
core   +1 more source

Small‐Molecule Regulators for Gene Switches to Program Mammalian Cell Behaviour

ChemBioChem, Volume 25, Issue 6, March 15, 2024.
Small molecules have been widely utilized within the synthetic biology community as trigger input for regulating implemented genetic circuit in engineered mammalian cells. Here, we described the most commonly used small molecules and their associated genetic switches, employed to program cell behaviors, particularly within a cell and gene therapy ...
Maysam Mansouri, Martin Fussenegger
wiley   +1 more source

The scatter plots between serum concentrations of asunaprevir and either Mac-2 binding protein glycosylation isomer (M2BPGi) Levels, FIB4 index, serum albumin levels and peripheral platelet counts.

, 2018
Serum asunaprevir concentrations were positively correlated with serum M2BPGi levels (r = 0.418 ...
Kayoko Sugawara (5848991), Yukinori Imai (5849006), Nobuaki Nakayama (5849003), Masamitsu Nakao (5848994), Mie Inao (5849000), Satoshi Mochida (156566), Jun-ichi Kouyama (661243), Daisuke Motoya (5848997), Yoshihito Uchida (661242), Kayoko Naiki (661244), Tomoaki Tomiya (479370)   +10 more
core   +1 more source